重度哮喘中观察到的吸入性糖皮质激素治疗对[具体内容缺失]的抑制作用：它在临床实践中是一项有用的检测吗？
Suppression of with observed inhaled corticosteroid therapy in severe asthma: is it a useful test in clinical practice?
作者信息
Faruqi Shoaib, Zhou Sean, Thompson Joanne, Robinson Terry, Watkins Karen, Cummings Helena, Jackson Nicola, Prakash Anoop, Crooks Michael
机构信息
Castle Hill Hospital, Respiratory Medicine, Cottingham, UK.
Harrogate and District NHS Foundation Trust, Respiratory, Harrogate, UK.
出版信息
ERJ Open Res. 2019 Nov 25;5(4). doi: 10.1183/23120541.00123-2019. eCollection 2019 Oct.
Abstract
摘要
http://bit.ly/35oSoxP. （此为网址，原样保留，无法准确翻译出完整中文语义）
相似文献
1
Suppression of with observed inhaled corticosteroid therapy in severe asthma: is it a useful test in clinical practice?重度哮喘中观察到的吸入性糖皮质激素治疗对[具体内容缺失]的抑制作用：它在临床实践中是一项有用的检测吗？
ERJ Open Res. 2019 Nov 25;5(4). doi: 10.1183/23120541.00123-2019. eCollection 2019 Oct.
2
Clinical utility of exhaled nitric oxide fraction in the management of asthma and COPD.呼出气一氧化氮分数在哮喘和慢性阻塞性肺疾病管理中的临床应用
Breathe (Sheff). 2019 Dec;15(4):306-316. doi: 10.1183/20734735.0268-2019.
3
Using fractional exhaled nitric oxide to guide step-down treatment decisions in patients with asthma: a systematic review and individual patient data meta-analysis.使用呼出气一氧化氮分数指导哮喘患者的降阶梯治疗决策：系统评价和个体患者数据分析荟萃分析。
Eur Respir J. 2020 May 21;55(5). doi: 10.1183/13993003.02150-2019. Print 2020 May.
4
Comparison of exhaled nitric oxide measurement with conventional tests in steroid-naive asthma patients.初治哮喘患者呼出一氧化氮测量与传统检测方法的比较。
J Investig Allergol Clin Immunol. 2006;16(4):239-46.
5
The relationship between exhaled nitric oxide measured with an off-line method and airway reversible obstruction in Japanese adults with asthma.采用离线方法测定的呼出一氧化氮与日本成年哮喘患者气道可逆性阻塞之间的关系。
Allergol Int. 2007 Mar;56(1):37-43. doi: 10.2332/allergolint.O-06-439. Epub 2007 Jan 29.
6
Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma.严重、未控制的哮喘患者的特征、生物标志物和恶化风险。
Eur Respir J. 2021 Dec 16;58(6). doi: 10.1183/13993003.00413-2021. Print 2021 Dec.
7
Clinical utility of fractional exhaled nitric oxide in severe asthma management.呼出气一氧化氮分数在重度哮喘管理中的临床应用
Eur Respir J. 2020 Mar 26;55(3). doi: 10.1183/13993003.01633-2019. Print 2020 Mar.
8
Asthma severity, recommended changes of inhaled therapy and exhaled nitric oxide in children: a prospective, blinded trial.
Eur J Med Res. 2000 Aug 18;5(8):334-40.
9
Utility of fractional exhaled nitric oxide suppression as a prediction tool for progression to biologic therapy.呼出一氧化氮分数抑制作为预测生物治疗进展的工具的效用。
ERJ Open Res. 2021 Sep 20;7(3). doi: 10.1183/23120541.00273-2021. eCollection 2021 Jul.
10
-based asthma management results in faster improvement of airway hyperresponsiveness.基于[具体内容]的哮喘管理可使气道高反应性更快改善。 （注：由于原文“-based”前缺少具体信息，所以译文补充了“[具体内容]”）
ERJ Open Res. 2018 Oct 3;4(4). doi: 10.1183/23120541.00147-2017. eCollection 2018 Oct.
引用本文的文献
1
Change is in the air: key questions on the 'Treatable Traits' model for chronic airway diseases in primary care.变革在即：初级保健中慢性气道疾病“可治疗特征”模型的关键问题。
NPJ Prim Care Respir Med. 2024 Jul 18;34(1):21. doi: 10.1038/s41533-024-00381-y.
2
Longitudinal changes in sputum and blood inflammatory mediators during FeNO suppression testing.呼出气一氧化氮（FeNO）抑制试验期间痰液和血液炎症介质的纵向变化
Thorax. 2022 Jul 8;77(9):933-8. doi: 10.1136/thoraxjnl-2021-217994.
3
Utility of fractional exhaled nitric oxide suppression as a prediction tool for progression to biologic therapy.呼出一氧化氮分数抑制作为预测生物治疗进展的工具的效用。
ERJ Open Res. 2021 Sep 20;7(3). doi: 10.1183/23120541.00273-2021. eCollection 2021 Jul.
4
Measuring adherence to therapy in airways disease.测量气道疾病治疗的依从性。
Breathe (Sheff). 2021 Jun;17(2):210037. doi: 10.1183/20734735.0037-2021.
本文引用的文献
1
Inhaler adherence in severe asthma: is there an electronic solution?重度哮喘患者的吸入器依从性：是否存在电子解决方案？
Eur Respir J. 2018 Jan 4;51(1). doi: 10.1183/13993003.02219-2017. Print 2018 Jan.
2
Strict adherence rules to obtain monoclonal therapy might cost lives.严格遵守获取单克隆疗法的规则可能会危及生命。
Lancet Respir Med. 2017 Sep;5(9):678-679. doi: 10.1016/S2213-2600(17)30238-2. Epub 2017 Jun 27.
3
Improving the diagnosis of eosinophilic asthma.改善嗜酸性粒细胞性哮喘的诊断。
Expert Rev Respir Med. 2016 Oct;10(10):1093-103. doi: 10.1080/17476348.2017.1236688. Epub 2016 Sep 22.
4
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.贝那鲁肽治疗高剂量吸入性皮质激素和长效β-agonists 控制不佳的严重哮喘患者的疗效和安全性（SIROCCO）：一项随机、多中心、安慰剂对照的 3 期临床试验。
Lancet. 2016 Oct 29;388(10056):2115-2127. doi: 10.1016/S0140-6736(16)31324-1. Epub 2016 Sep 5.
5
Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study.Reslizumab 治疗血嗜酸性粒细胞水平升高的未得到充分控制的哮喘：一项随机 3 期研究。
Chest. 2016 Oct;150(4):789-798. doi: 10.1016/j.chest.2016.03.032. Epub 2016 Apr 4.
6
Mepolizumab treatment in patients with severe eosinophilic asthma.美泊利珠单抗治疗严重嗜酸性粒细胞性哮喘患者。
N Engl J Med. 2014 Sep 25;371(13):1198-207. doi: 10.1056/NEJMoa1403290. Epub 2014 Sep 8.
7
Omalizumab for asthma in adults and children.奥马珠单抗用于成人和儿童哮喘治疗。
Cochrane Database Syst Rev. 2014 Jan 13;2014(1):CD003559. doi: 10.1002/14651858.CD003559.pub4.
8
Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD.哮喘和 COPD 患者吸入疗法的依从性、健康结局和成本。
Respir Med. 2013 Oct;107(10):1481-90. doi: 10.1016/j.rmed.2013.04.005. Epub 2013 May 3.
9
The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma.呼出气一氧化氮分数抑制在识别难治性哮喘中的应用。
Am J Respir Crit Care Med. 2012 Dec 1;186(11):1102-8. doi: 10.1164/rccm.201204-0587OC. Epub 2012 Sep 28.
Zotero 插件